Sun Pharma: Eloxatin settlement a boon in disguise?

Generic players including Hospira, Teva, Fresenius Kabi and Sandoz have agreed to cease marketing their generic versions of Eloxatin in late June and resume selling with licensed versions in Aug 2012, as per a settlement with Sanofi�-Aventis (Innovator). This development is a lucrative opportunity for SUNP, since it appears that it be the only generic in the market during June 11�-Aug 12. But one has to wait and watch if SUNP enters into a similar agreement. Investors are recommended to maintain neutral rating on the stock

http://digg.com/u1T5V4